Financing ·
Grace Therapeutics, Inc. announced a private placement of its common stock on August 4, 2026, closing on August 6, 2026
GRCEGrace Therapeutics, Inc.
Grace Therapeutics, Inc. announced a private placement of its common stock on August 4, 2026, closing on August 6, 2026. The company sold 4,761,904 shares at $2.10 per share to institutional and accredited investors, generating approximately $10 million in gross proceeds before fees. Craig-Hallum Capital Group LLC acted as the placement agent. Proceeds will support manufacturing and regulatory work for GTx-104, extending the cash runway to the end of calendar 2028. The company initiated a dual-source manufacturing strategy for GTx-104, transferring technology to a second U.S.-based contract manufacturer while remediation efforts continue at the current facility. NDA resubmission timing depends on which manufacturing pathway reaches readiness first. Grace Therapeutics is a late-stage biopharmaceutical company developing novel drug delivery technologies and clinical-stage assets for rare diseases.